Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02885818

Acronym

ABATACEPT_B

Enrollment

Registered

2016-09-01

Start date

2014-10-01

Completion date

2018-01-11

Last updated

2019-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential effects on B cells are not well described. This study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood B cells in patients with RA.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* RA as defined by ACR/EULAR criteria * Clinical indication to start abatacept therapy

Exclusion criteria

* Treatment by rituximab in the previous year

Design outcomes

Primary

Measure	Time frame	Description
Peripheral blood B-cell phenotype changes	3 months	Measure of the proportion of the main B-cell subsets (transitional, naïve, memory, plasmablasts) by FACS analysis before abatacept initiation and 3 months later.

Secondary

Measure	Time frame	Description
In vitro B-cell function and regulatory properties	3 months	In vitro culture of B cells from the patients to assess B cell inhibition of T cell proliferation before abatacept initiation and 3 months later.

Countries

France

Outcome results